Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 6/20 | 0.47 |
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30037693 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL18917031 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL666140 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL30801428 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL417576 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL29388642 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL30059530 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL2477982 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL128589 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL3161061 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026041386-A1 | ANHYDROUS COMPOSITION COMPRISING MONOESTERS AND MAINLY PETROLATUM | UNILEVER IP HOLDINGS B.V. (NL) | 2026-02-26 | — | — | WO | claimed |
| US-20070287688-A1 | Pharmaceutical Compositions for Topical Application | MACRO CHEM CORPORATION | 2007-12-13 | — | — | US | claimed |
| EP-1648364-A2 | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATION | MacroChem Corporation (US) | 2006-04-26 | — | — | EP | claimed |
| WO-2005007100-A2 | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATION | MACROCHEM CORPORATION (US) | 2005-01-27 | — | — | WO | claimed |
| WO-2026041386-A1 | ANHYDROUS COMPOSITION COMPRISING MONOESTERS AND MAINLY PETROLATUM | UNILEVER IP HOLDINGS B.V. (NL) | 2026-02-26 | — | — | WO | disclosed |
| EP-4611105-A1 | NONAQUEOUS ELECTROLYTE AND CLAY-TYPE LITHIUM ION SECONDARY BATTERY USING SAME | Kyocera Corporation (JP) | 2025-09-03 | — | — | EP | disclosed |
| EP-4611091-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM-ION SECONDARY BATTERY USING SAME | Kyocera Corporation (JP) | 2025-09-03 | — | — | EP | disclosed |
| CN-120092348-A | Nonaqueous electrolyte solution and lithium ion secondary battery using same | 京瓷株式会社 | 2025-06-03 | — | — | CN | disclosed |
| CN-120092347-A | Nonaqueous electrolyte and clay-type lithium ion secondary battery using same | 京瓷株式会社 | 2025-06-03 | — | — | CN | disclosed |
| US-20240396076-A1 | LITHIUM ION SECONDARY BATTERY AND NON-AQUEOUS ELECTROLYTIC SOLUTION | KYOCERA CORPORATION (JP) | 2024-11-28 | — | — | US | disclosed |
| EP-4398365-A1 | LITHIUM ION SECONDARY BATTERY AND NONAQUEOUS ELECTROLYTE SOLUTION | Kyocera Corporation (JP) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024090573-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM-ION SECONDARY BATTERY USING SAME | 京セラ株式会社 | 2024-05-02 | — | — | WO | disclosed |
| US-6881522-B2 | Nonaqueous electrolytic solution and lithium secondary battery | UBE INDUSTRIES, LTD. (JP) | 2005-04-19 | — | — | US | disclosed |
| WO-2005007100-A2 | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATION | MACROCHEM CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20040058251-A1 | Nonaqueous electrolytic solution and lithium secondary battery | HAMAMOTO TOSHIKAZU (JP) | 2004-03-25 | — | — | US | disclosed |
| US-6703001-B1 | TRIS(2-ETHYLHEXYL)-4,4',4?-(1,3,5-TRIAZINE-2,4,6-TRIYLIMINO) TRISBENZOATE AND ISODECYL NEOPENTANOATE MIXTURE | BEIERSDORF AG (DE) | 2004-03-09 | — | — | US | disclosed |
| EP-1077673-B1 | COSMETIC AND DERMATOLOGICAL LIGHT-PROTECTIVE FORMULATIONS CONTAINING TRIAZINE DERIVATIVES AND ONE OR SEVERAL ESTERS OF BRANCHED-CHAIN CARBOXYLIC ACIDS AND BRANCHED-CHAIN ALCOHOLS | BEIERSDORF AG (DE) | 2003-09-03 | — | — | EP | disclosed |
| EP-1311018-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERY | Ube Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-1077673-A1 | COSMETIC AND DERMATOLOGICAL LIGHT-PROTECTIVE FORMULATIONS CONTAINING TRIAZINE DERIVATIVES AND ONE OR SEVERAL ESTERS OF BRANCHED-CHAIN CARBOXYLIC ACIDS AND BRANCHED-CHAIN ALCOHOLS | Beiersdorf Aktiengesellschaft (DE) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058102-A1 | COSMETIC AND DERMATOLOGICAL LIGHT-PROTECTIVE FORMULATIONS CONTAINING TRIAZINE DERIVATIVES AND ONE OR SEVERAL ESTERS OF BRANCHED-CHAIN CARBOXYLIC ACIDS AND BRANCHED-CHAIN ALCOHOLS | BEIERSDORF AG (DE) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287688-A1 | Pharmaceutical Compositions for Topical Application | CYP8B1, NR1H3, NR1H2 | NAAA 2967/4885EPHX1 191/4885TSHR 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.